We permit the publication of our auditors’ report, provided the report is published in full only and is accompanied by the full financial statements to which our auditors’ report relates, and is only published on an access-controlled page on your website, to enable users to verify that an auditors’ report by independent accountants has been commissioned by the directors and issued. Such permission to publish is given by us without accepting or assuming any responsibility or liability to any third party users save where we have agreed terms with them in writing.

Our consent is given on condition that before any third party accesses our auditors’ report via the webpage they first document their agreement to the following terms of access to our report via a click-through webpage with an 'I accept' button. The terms to be included on your website are as follows:

I accept and agree for and on behalf of myself and the Trust I represent (each a "recipient") that:

  1. PricewaterhouseCoopers LLP (“PwC”) accepts no liability (including liability for negligence) to each recipient in relation to PwC’s report. The report is provided to each recipient for information purposes only. If a recipient relies on PwC’s report, it does so entirely at its own risk;
  2. No recipient will bring a claim against PwC which relates to the access to the report by a recipient;
  3. Neither PwC’s report, nor information obtained from it, may be made available to anyone else without PwC’s prior written consent, except where required by law or regulation; and
  4. PwC’s report was prepared with Hermes Property Unit Trust's interests in mind. It was not prepared with any recipient's interests in mind or for its use. PwC’s report is not a substitute for any enquiries that a recipient should make. The financial statements are as at 25 March 2017, and thus PwC’s auditors’ report is based on historical information. Any projection of such information or PwC’s opinion thereon to future periods is subject to the risk that changes may occur after the reports are issued and the description of controls may no longer accurately portray the system of internal control. For these reasons, such projection of information to future periods would be inappropriate.
  5. PwC will be entitled to the benefit of and to enforce these terms.
I accept

1. Select your country

  • United Kingdom
  • Austria
  • Australia
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Iceland
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Singapore
  • Spain
  • Sweden
  • Switzerland
  • USA
  • Other

2. Select your investor type

  • Financial Advisor
  • Discretionary Investment Manager
  • Wealth Manager
  • Family Office
  • Institutional Investor
  • Investment Consultant
  • Charity, Foundation & Endowment Investor
  • Retail Investor
  • Press
  • None of the above

3. Accept our terms and conditions

By clicking Proceed I confirm I have read the important information and agree to the terms of use.


The Hermes Investment Management website uses cookies to remember your preferences and help us improve the site.
By proceeding, you agree to cookies being placed on your computer.
Read our privacy and cookie policy.

Stars in their eyes...

Home / Press Centre / Stars in their eyes…

James Rutherford, Portfolio Manager
14 September 2017
ArchivedEuropean Equities

The stars have been aligned for European equities for much of 2017. The markets progress and company earnings have for the first time in many years been free of external shocks, recessions, sanctions, credit or currency crisis, surprise policy shocks. James Rutherford, European Equities Portfolio Manager at Hermes Investment Management, discusses how this makes 2017 suddenly an unusual year as growth forecasts have held up, unlike in many recent years where estimates have dwindled over the course of the year.

Despite the positive start, some caution remains as Euro strength (notably against the US dollar) will provide a headwind to reported numbers over coming quarters. An element of this has been discounted; overseas earners have underperformed domestic-focused stocks. This is a translation issue rather than a transactional issue so the core organic fundamentals remain firm. The Euro strength may see Draghi soften his tapering stance or maybe the Fed becoming more hawkish. One must remember these sizeable currency moves have moved with rhetoric and political perception, not absolute policy actions, so reversals are easy to see. A more dovish tone would suppress yields in Europe and support a more growth-oriented stance.

The recent market has been characterised by narrowing breadth with the strength of the Euro pushing investors to more domestic plays, particularly financials and utilities. These are not growth areas and would appear to be more default type positioning. Stock reactions to results would suggest much of the good news was discounted, with companies who beat or exceeded expectations being unrewarded with positive share performance and misses being severely punished even for short term issues. This highlights the momentum driven nature of the market where short-term issues are sold off and the money moves elsewhere. Indiscriminate by nature, but this creates opportunities for those willing and patient to see beyond that particularly moment. We have taken advantage of some situations where stocks have been unfairly punished, and have removed stocks where fundamental headwinds would appear more permanent. We can see that earnings growth for next year, whilst still positive, will temper somewhat as hedging policies roll off and reveal the negative impact of the strong Euro. Our focus has been on stocks where we see an acceleration in growth rates going forward into 2018. Qiagen has been initiated as a new position, and we have added to positions in Novo Nordisk, Worldpay, Convatec.

Until recently, Qiagen – a manufacturer of medical devices and tests – has seen growth held back by intense competition to its HPV test, one of its most important business areas. This is now coming to an end, allowing the company to accelerate growth driven by two exciting new products. With the launch of their Next Generation Sequencing instrument, which is used by doctors and researchers to analyse diseases to a level of detail not previously possible, Qiagen is exposed to a market that could be worth tens of billions of dollars. Meanwhile, the QuantiFERON Tuberculosis test, the next generation test for the disease which has significant benefits over the traditional test, still only has a 15% share in this market and can continue to take share from the 100 year old skin tests.

Novo Nordisk is focused on the growing diabetes market, but had seen sentiment turn against it due to concerns over pricing in one of the larger segments of the market. However, we believe the long-term fundamental story – exposure to a structurally growing market and a strong product pipeline – remain intact. We are particularly positive on the prospects for a number of the company’s new and upcoming drugs such as Saxenda for weight loss which is a new market that Novo Nordisk is building from the ground up and Semaglutide, a drug that looks to have far better efficacy than incumbent products in the GLP-1 market.

ConvaTec is a leading player in the global wound care and ostomy markets. Recently we have been able to increase our position in the stock because of short-term issues which have concerned investors, such as temporary manufacturing problems and higher costs associated with launching innovative new products. However, these have no bearing on the long-term investment thesis – exposure to attractive end markets and the opportunity to increase margins to in-line with peers. Indeed, the main investor concerns during the IPO process; the company’s ability to turnaround performance in the key Ostomy division and achieve its Margin Improvement Programme targets, appear to be exceeding expectations.

In a world where debt continues to accumulate, growth will continue to be relatively benign and characterised by short and shallow cycles. Markets and stocks will remain highly sensitive to policy and currency moves and our focus will remain on the structural plays, where earnings and cashflows are driven by factors independent of the economic environment but also recognising that stocks don't operate in a vacuum, remembering our old adage that markets are not economies.

Share this post:
James Rutherford Portfolio Manager James Rutherford joined Hermes in December 2006 and is the Co-Head of Investments for Hermes European Equities and Co-Portfolio Manager for the Hermes European Alpha product. After graduating, James joined Fidelity as a Pan-European Research Analyst, initially specialising in areas such as property, transportation, autos and media. In 1994, he became portfolio assistant to Graham Clapp, and quickly progressed to become a Pan-European institutional portfolio manager in 1995. James also co-managed the UK Recovery Trust, which was ranked first in its peer group during that period. Over 11 years James came to manage a $19bn portfolio of Pan-European institutional funds, and he remained at Fidelity until joining Hermes. James has over 20 years of experience in the investment industry and graduated from the London School of Economics in 1988.
Read all articles by James Rutherford

Find posts by author

  • Alex Knox, ACA
  • Amy Wilson
  • Andrew Jackson
  • Andrew Parry
  • Claire Gavini
  • Dr Michael Viehs
  • Emeric Chenebaux
  • Eoin Murray
  • Geoffrey Wan, CFA
  • Harriet Steel
  • Ilana Elbim
  • Ingrid Holmes
  • Jonathan Pines, CFA
  • Joseph Buckley
  • Kimberley Lewis
  • Louise Dudley
  • Mark Sherlock, CFA
  • Martin Todd
  • Maxime Le Floch, CFA
  • Michael Russell, CFA
  • Michael Vaughan
  • Neil Williams
  • Nick Spooner
  • Nina Röhrbein
  • Peter Hofbauer
  • Philip Nell
  • Saker Nusseibeh
  • Silvia Dall’Angelo
  • Tatiana Bosteels
  • Tim Crockford
  • Tommaso Mancuso
  • Yasmin Chowdhury

Find posts by category

  • archived
  • european equities

Press contacts